Previous 10 | Next 10 |
SAN FRANCISCO , July 20, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor in...
Gainers: Midatech Pharma (NASDAQ: MTP ) +42% . Rayonier Advanced Materials (NYSE: RYAM ) +20% . Gannett (NYSE: GCI ) +19% . CrowdStrike Holdings (NASDAQ: CRWD ) +15% . Camber Energy (NYSEMKT: CEI ) +14% . Skechers U.S.A. (NYSE: SKX ) +13% . Powerbridge Technologies (NASDAQ: PBT...
Marker Therapeutics ( MRKR -17.6% ) slumps on 12% higher volume in early trade in response to preliminary data from a Phase 1/2 clinical trial evaluating its MultiTAA T cell therapy in patients with pancreatic adenocarcinoma, the most common type of pancreatic cancer. Investors...
Jaguar Health (NASDAQ: JAGX ) -31% . More news on: Jaguar Health, Inc., J. C. Penney Company, Inc., Marker Therapeutics, Inc., Stocks on the move, Read more ...
Noteworthy events during the week of July 21 - 27 for healthcare investors. More news on: Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Healthcare stocks news, , Read more ...
HOUSTON , July 17, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...
by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...
CannTrust Holdings (NYSE: CTST ) initiated with Buy rating and $7 (41% upside) price target at Citigroup. More news on: Inogen, Inc., CannTrust Holdings Inc., Marker Therapeutics, Inc., Healthcare stocks news, , Read more ...
HOUSTON , June 20, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications...
Marker Therapeutics ( MRKR ) is gearing up for a big catalyst in Q3 of 2019. This is going to be data from its phase 1/2 study using its MultiTAA cell therapy product to treat patients with pancreatic solid tumors. The MultiTAA product from the biotech offers many advantages over current CAR...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...